| __timestamp | BioMarin Pharmaceutical Inc. | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 461543000 | 33472000 |
| Thursday, January 1, 2015 | 634806000 | 47368000 |
| Friday, January 1, 2016 | 661905000 | 66871000 |
| Sunday, January 1, 2017 | 610753000 | 50675000 |
| Monday, January 1, 2018 | 696328000 | 78821000 |
| Tuesday, January 1, 2019 | 715007000 | 91944000 |
| Wednesday, January 1, 2020 | 628116000 | 111234000 |
| Friday, January 1, 2021 | 628793000 | 207447000 |
| Saturday, January 1, 2022 | 649606000 | 267587000 |
| Sunday, January 1, 2023 | 746773000 | 303055000 |
| Monday, January 1, 2024 | 747184000 |
Unleashing the power of data
In the competitive world of biopharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, BioMarin Pharmaceutical Inc. and HUTCHMED (China) Limited have demonstrated contrasting approaches to R&D investment. BioMarin's R&D expenses have consistently outpaced those of HUTCHMED, with a notable increase of approximately 62% from 2014 to 2023. In 2023, BioMarin's R&D spending reached its peak, nearly doubling HUTCHMED's investment. Meanwhile, HUTCHMED has shown a remarkable growth trajectory, with its R&D expenses increasing almost ninefold over the same period. This trend highlights the dynamic nature of the biopharmaceutical industry, where strategic investments in R&D can drive innovation and competitive advantage. As these companies continue to push the boundaries of medical science, their R&D spending patterns offer valuable insights into their future potential.
Research and Development Expenses Breakdown: Novartis AG vs BioMarin Pharmaceutical Inc.
R&D Insights: How Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc. Allocate Funds
Comparing Innovation Spending: Zoetis Inc. and BioMarin Pharmaceutical Inc.
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and HUTCHMED (China) Limited
BioMarin Pharmaceutical Inc. or Pharming Group N.V.: Who Invests More in Innovation?
Analyzing R&D Budgets: BioMarin Pharmaceutical Inc. vs Viridian Therapeutics, Inc.
Research and Development Expenses Breakdown: Ultragenyx Pharmaceutical Inc. vs HUTCHMED (China) Limited
Xenon Pharmaceuticals Inc. or HUTCHMED (China) Limited: Who Invests More in Innovation?
R&D Spending Showdown: Catalyst Pharmaceuticals, Inc. vs HUTCHMED (China) Limited
Research and Development Expenses Breakdown: HUTCHMED (China) Limited vs Taro Pharmaceutical Industries Ltd.
Comparing Innovation Spending: HUTCHMED (China) Limited and Galapagos NV